Compare HAFC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | OMER |
|---|---|---|
| Founded | 1982 | 1994 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.9M | 894.8M |
| IPO Year | N/A | N/A |
| Metric | HAFC | OMER |
|---|---|---|
| Price | $27.23 | $11.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $31.33 | ★ $32.50 |
| AVG Volume (30 Days) | 315.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.65 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.25 | $2.95 |
| 52 Week High | $30.20 | $17.65 |
| Indicator | HAFC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 49.14 |
| Support Level | $26.36 | $11.00 |
| Resistance Level | $28.43 | $12.45 |
| Average True Range (ATR) | 0.84 | 0.57 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 54.04 | 60.53 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.